FDA Clearance Tracker · K251595
COVID-19 Detect Rapid Self -Test
Last checked: Nov 20, 2026Latest source record: Oct 12, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Oct 12, 2025
Substantially Equivalent
Time to decision
138 days
Received May 27, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K251595
- Device name
- COVID-19 Detect Rapid Self -Test
- Applicant
- InBios International, Inc.
- Applicant location
- Seattle, WA
- Received
- May 27, 2025
- Decided
- Oct 12, 2025
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device type
- Over-The-Counter Covid-19 Antigen Test (QYT)
- Device class
- Class II
- Regulation
- 21 CFR 866.3984
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code QYT. The earliest in FDA's data is K230828, decided Nov 9, 2023.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K251595
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for InBios International, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K233358 · Decided Aug 23, 2024 · 329 days after receipt
Device type: Simple Point-Of-Care Device To Directly Detect Sars-Cov-2 Viral Targets From Clinical Specimens In Near-Patient Settings (QVF) · Laboratory Medicine & Pathology
- Active Anthrax DetectTM Plus Rapid TestNew device typeDe Novo
DEN220044 · Decided Feb 3, 2023 · 210 days after receipt
Device type: Simple In Vitro Diagnostic Device For The Detection Of Secreted Proteins From Bacillus Spp. In Human Clinical Samples (QUU) · Laboratory Medicine & Pathology
- ZIKV Detect 2.0 IgM Capture ELISANew device typeDe Novo
DEN180069 · Decided May 23, 2019 · 148 days after receipt
Device type: Zika Virus Serological Reagents (QFO) · Laboratory Medicine & Pathology
2 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.